Clinical trials: Persistent Asthma
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00772538
- Testing
- tiotropium 5mcg/day
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Boehringer Ingelheim
Asthma
As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma
The aim of this study is to reveal that inhaled corticosteroid therapy combined with a short-acting beta2- agonist given on a symptom driven basis is as effective as traditional asthma therapy.
- Trial name
- NCT00382889
- Testing
- beclomethasone/salbutamol combination, beclomethasone, salbutamol
- Where
- 25 sites in Austria, Italy and 2 more
- Volunteers
- 480 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)
The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol…
- Trial name
- NCT00379288
- Testing
- mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID, Fluticasone/Salmeterol 250/50 mcg BID
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma.
- Trial name
- NCT01257230
- Testing
- tiotropium Respimat low dose, tiotropium Respimat high dose
- Where
- 66 sites in United States, Chile and 10 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
Asthma
Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand
The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.
- Trial name
- NCT00800241
- Where
- 14 sites in Thailand
- Volunteers
- 1,020 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Breathing Exercises for Asthma
Despite the advances in pharmacological therapy for asthma, there has been an increasing worldwide interest in alternative therapies for asthma.
- Trial name
- NCT02151422
- Testing
- Breathing exercise
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Asthma
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma
- Trial name
- NCT00461500
- Testing
- Salmeterol xinafoate/fluticasone propionate combination, Fluticasone propionate
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Persistent Asthma
Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients
Clinical trial to demonstrate whether, in patients with moderate asthma, to treat with IC / LABA a medium dose, but not controlled, to achieve a similar degree of control by making a progressive increase of that treatment (CI /…
- Trial name
- NCT04271839
- Testing
- fluticasone/formoterol k-haler (medium strength), Standard of care (ICs/LABA high strength)
- Sponsor
- Mundipharma Pharmaceuticals S.L.
Asthma Severe Persistent Controlled
Phase I Clinical Trial of TQC2731 Injection
This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.
- Trial name
- NCT04923607
- Testing
- TQC2731
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
Mobile Phone Based Structured Intervention
Although asthma outcomes can be improved with structured care, less than half of people with asthma achieve good control. Part of the problem is poor adherence with self-monitoring and preventive drug regimes.
- Trial name
- NCT00512837
- Testing
- Mobile phone technology
- Where
- United Kingdom
- Volunteers
- 312 people
- Sponsor
- University of Aberdeen
Asthma
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
The primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age…
- Trial name
- NCT00500539
- Testing
- omalizumab
- Where
- 31 sites in United States, Argentina and 1 more
- Volunteers
- 155 people
- Sponsor
- Novartis
Asthma
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
Study No.001 about Budesonide/Formoterol use in ASthMA sponsored by Agenzia Italiana del FArmaco (Italian Drug Agency) (AIFA-ASMA-BF-001) The aim of the study is to verify whether asthma not controlled by low doses inhaled…
- Trial name
- NCT00849095
- Testing
- budesonide/formoterol combination (PRN), budesonide/formoterol combination, terbutaline
- Where
- 31 sites in Italy
- Volunteers
- 860 people
- Sponsor
- Università degli Studi di Ferrara
Asthma, Asthma Chronic
Improving the Quality of Care for Asthma Patients at Risk of Exacerbations
The goal of this trial test two known effective asthma strategies. Treatment guidelines recommend combination therapy of inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA) inhaled medications.
- Conditions
- Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
- Trial name
- iCARE (NCT06596512)
- Testing
- PARTICS using a single ICS add on, MART
- Where
- 6 sites in United States
- Volunteers
- 4,100 people
- Sponsor
- Brigham and Women's Hospital
Persistent Asthma
Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma
Evaluation of the frequency of limitation of activity, depending on gender and age-group, in patients with persistent asthma consulting a general practitioner
- Trial name
- ASMAVIE (NCT01078688)
- Where
- 724 sites in France
- Volunteers
- 1,942 people
- Sponsor
- AstraZeneca
Asthma
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once…
- Trial name
- NCT01134042
- Testing
- Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder
- Where
- 71 sites in United States, Germany and 4 more
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Severe Persistent Asthma
A National Program for Severe Asthma: The Canadian Severe Asthma Network
The Canadian Severe Asthma Network (CSAN) was developed to gain a better understanding of the clinical, environmental, socio-economic, work-related, and biological characteristics of severe asthmatics (SA) that may account for…
- Trial name
- CSAN (NCT00954850)
- Where
- Canada
- Sponsor
- University of Alberta
Asthma; Eosinophilic
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
Dose escalation of reslizumab can ameliorate sputum eosinophilia in severe asthmatics who have persistent sputum eosinophilia despite treatment with reslizumab at the standard dose.
- Trial name
- NCT04710134
- Testing
- Reslizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Asthma
Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)
The aim of the study is to compare the safety and efficacy of ciclesonide versus fluticasone propionate on the lung function, symptoms, use of rescue medication, and occurrence of side effects (such as candidiasis, hoarseness) in…
- Trial name
- NCT00163319
- Testing
- Ciclesonide
- Where
- 89 sites in Belgium, France and 5 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma
Effects of Particle Size in Small Airways Dysfunction
The airways in the lungs get smaller the further into the lungs they go. Most simple measurements of lung function only reflect the larger 'central' airways and do not provide information on the smaller 'peripheral' airways.
- Trial name
- MAN03 (NCT01892787)
- Testing
- Formoterol, Salmeterol
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- University of Dundee